Opdivo and Asphyxia - a phase IV clinical study of FDA data

Summary:

Asphyxia is reported as a side effect among people who take Opdivo (nivolumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Amaryl, and have Oesophageal carcinoma.

The phase IV clinical study analyzes which people have Asphyxia when taking Opdivo. It is created by eHealthMe based on reports of 56,294 people who have side effects when taking Opdivo from the FDA, and is updated regularly.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

What is Asphyxia?

Asphyxia (a condition in which there is an extreme decrease in the concentration of oxygen in the body) is found to be associated with 556 drugs and 821 conditions by eHealthMe. Check the latest studies of Asphyxia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 21, 2026

56,294 people reported to have side effects when taking Opdivo.
Among them, 15 people (0.03%) have Asphyxia.

Among these 15 people:

How long have people been on Opdivo when they have Asphyxia? *

What is the gender of people who have Asphyxia when taking Opdivo? *

female: 10 %
male: 90 %

What is the age of people who have Asphyxia when taking Opdivo? *

What are other drugs people take besides Opdivo? *

What are other side effects people have besides Asphyxia? *

Rashes (redness): 4 people, 26.67%
Itching: 4 people, 26.67%
Pneumonia Aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree): 3 people, 20.00%
Hepatic Function Abnormal: 3 people, 20.00%
Sputum Retention: 2 people, 13.33%
Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin): 2 people, 13.33%
Adrenal Insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids): 2 people, 13.33%
Loss Of Consciousness: 2 people, 13.33%
Oedema (fluid collection in tissue): 2 people, 13.33%
Malignant Neoplasm Progression (cancer tumour came back): 1 person, 6.67%

What are the existing conditions these people have? *

Oesophageal Carcinoma (cancer tumour of oesophagus): 4 people, 26.67%
Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 20.00%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 2 people, 13.33%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 1 person, 6.67%
Renal Cell Carcinoma (a kidney cancer): 1 person, 6.67%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 1 person, 6.67%
Bronchial Carcinoma (lung cancer): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Opdivo and have Asphyxia?

- Check whether Asphyxia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opdivo:

Opdivo (56,331 reports)

Asphyxia treatments and more:

Asphyxia (9,188 reports)

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Asphyxia:

Asphyxia (556 drugs)

Browse all the conditions that are associated with Asphyxia:

Asphyxia (821 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nivolumab (the active ingredients of Opdivo) and Opdivo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.